Hong Kong stock surged | Donyang Guangyao (06887.HK) rose nearly 5% in intra-day trading as domestically developed new drug for hepatitis B nucleic acid was approved for clinical trials.

According to the Wise Finance APP, Dongyangguang Pharmaceutical (06887.HK) rose nearly 5% during trading hours, as of the time of reporting, it rose 3.25% to 48.88 Hong Kong dollars, with a turnover of 23.2866 million Hong Kong dollars.